UPDATE: Canaccord Genuity Raises HeartWare International's PT

According to a research report published this morning, Canaccord Genuity has increased HeartWare International's

PT from $95 to $101. In the report, Canaccord Genuity commented, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September." Canaccord Genuity maintains its Buy rating on HeartWare International, which closed yesterday at $77.14.